Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled after Sanofi struck a licensing deal worth up to $1.2bn to commercialise ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi (SNY, FR:SAN). Novavax shares were up 133% in recent trading at $10.11.
(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement ... receive tiered royalties on any vaccine sales, said Sanofi is also taking a minority ...
Sanofi will also have a non-exclusive license to use Novavax’s Matrix-M adjuvant in other vaccine products ... down about 5% in the past 12 months through Thursday’s close. The deal is a boost for ...
Sanofi will also have a non-exclusive license to use Novavax’s Matrix-M adjuvant in other vaccine products ... months through Thursday’s close. The deal is a boost for Novavax which is ...
Patrick van Katwijk / Contributor / Getty Images Novavax shares more than doubled in intraday trading Friday as it announced a $1.2 billion deal to license its vaccine technology to Sanofi.
Sanofi will also have a non-exclusive license to use Novavax's Matrix-M adjuvant in other vaccine products ... 12 months through Thursday's close. The deal is a boost for Novavax which is in ...
The vaccine maker said overnight that it has reached a licensing agreement ... As part of the deal, Sanofi will take a minority equity investment in Novavax. Write to Dean Seal at dean.seal@ ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
The deal also entitles Novavax to an upfront ... as well as royalties. Sanofi, one of the world's largest vaccine makers, will gain a license to co-sell Novavax's vaccine in most countries and ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled after Sanofi struck a licensing deal worth up to $1.2bn to commercialise ...